Eylea Sales Continue to Increase; Lucentis Gains New Indications

August 11, 2017: By Joan McKenna

Lucentis and EyleaRegeneron reported that its Q2-2017 net sales of Eylea in the US totaled $919 million, an increase of 11 percent over Q2-2016 net sales of $831 million.

Bayer commercializes Eylea outside the US, and its Q2-2017 net sales of the anti-VEGF increased to $542 million, up 10 percent over $486 million in Q2-2016. Regeneron said it recognized $191 million from its share of Bayer’s Eylea sales, compared with $167 million in Q2-2016.

Roche reported that Lucentis’ Q2-2017 sales in the US totaled about $348 million (CHF $335 million, conversion Aug. 11, 2017), a 5 percent decline from Q2-2016 sales. Still, revenues for the retinal treatment were up 2 percent for the first half of the year at $755 million (CHF $727 million). Roche noted that Lucentis gained US FDA approval for all forms of diabetic retinopathy during the quarter.

Novartis sells Lucentis outside the US, and its Q2-2017 sales totaled $477 million, up 5 percent in constant currency but flat in US dollars. Novartis said Lucentis has gained added labeling for choroidal neovascularization in 51 countries, as well as Europe, where the indication was approved in 2016, and the Lucentis prefilled syringe has launched in 32 countries.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022